Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc.APUS · Entity 8263 | Director | November 11, 2025 | November 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Apimeds Pharmaceuticals US, Inc.
Report date November 11, 2025 · Filed November 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.67 · Expires 2035-11-11 | Direct | 10,000 |
Reported balance
After 2025-11-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-11 · Grant · Acquired 10,000 · Balance 10,000 F1: The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's employment continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the Company's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full vest upon the occurrence of a Change in Control, as defined in the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's employment continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the Company's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full vest upon the occurrence of a Change in Control, as defined in the Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 11, 2025 Filed Nov 13, 2025 23:39 UTC | Apimeds Pharmaceuticals US, Inc. APUS · Entity 8263 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0002041300-25-000003 · primary_doc.xml · derivative · entry 1 Yoon Hankil · CIK 0002041300 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock, par value $0.01 per share · 10,000 shares Expires 2035-11-11 F1 · derivative.exercise_date: The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's employment continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the Company's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full vest upon the occurrence of a Change in Control, as defined in the Plan. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 22:55 UTC | Apimeds Pharmaceuticals US, Inc. APUS · Entity 8263 | GrantStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0002041300-25-000002 · primary_doc.xml · derivative · entry 1 Yoon Hankil · CIK 0002041300 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock, par value $0.01 per share · 3,000 shares Expires 2035-10-15 F1 · derivative.exercise_date: The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's service to the issuer continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the issuer's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full upon the occurrence of a Change in Control, as defined in the Plan. Read SEC document |
| May 16, 2025 Filed May 20, 2025 21:11 UTC | Apimeds Pharmaceuticals US, Inc. APUS · Entity 8263 | GrantStock Option (right to buy) · Derivative | 5,780 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001474506-25-000102 · primary_doc.xml · derivative · entry 1 Yoon Hankil · CIK 0002041300 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,780 Underlying: Common Stock, par value $0.01 per share · 5,780 shares Expires 2035-05-16 F1 · derivative.exercise_date: The option will vest in full and become exercisable on 05/16/2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.